Effect of intermittent versus continuous parathyroid hormone in the cardiovascular system of rats.
OBJECTIVE
PTH increases ionic calcium concentration in the serum, acting primarily on bone and kidney cells through the type 1 PTH receptor. Interestingly, PTH stimulates bone formation when administrated intermittently but causes severe bone loss with continuous administration. Daily injections of PTH are used as the most promising anabolic agent in the treatment of severe osteoporosis. Elevated PTH is reported an independent risk factor for left ventricle hypertrophy.


METHODS
in rats we investigated the effect of intermittent and continuous administration of PTH on blood pressure, heart rate and development of cardiac hypertrophy and fibrosis.


RESULTS
We did not find PTH to induce heart hypertrophy. In contrast, continuous administration of PTH the mRNA level of a hypertrophic marker gene, atrial natriuretic peptide. When comparing the effect of continuously versus injected PTH collagen 1 mRNA was significantly higher in continuously treated animals.


CONCLUSIONS
our data demonstrated a decrease in heart rate upon continuous administration of PTH in rats. No changes in blood pressure were observed. Moreover, neither intermittent nor continuous administration of PTH induced ventricular hypertrophy. But continuous PTH induced a marker of collagen 1. Thus, these data did not reveal any negative effects of the injection of PTH on the cardiovascular system.
Smajilovic
Sanela
S
Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark.
Schaal-Jensen
Rasmus
R
Jabbari
Reza
R
Smajilovic
Una
U
Haunso
Stig
S
Tfelt-Hansen
Jacob
J
Nephron. 1985;39(1):30-5
3969188
J Am Soc Nephrol. 2003 Apr;14(4):959-67
12660330
Endocrinology. 1992 Apr;130(4):2045-51
1312438
Am J Kidney Dis. 1997 Nov;30(5):606-20
9370175
J Am Soc Nephrol. 2004 Oct;15(10):2588-600
15466263
Miner Electrolyte Metab. 1995;21(1-3):67-71
7565465
Endocrinology. 1993 Aug;133(2):617-23
8393771
Endocrinology. 2003 Dec;144(12):5188-93
12970167
Endocrinology. 2003 Mar;144(3):1053-61
12586782
Cardiovasc Res. 2007 Aug 1;75(3):457-67
17466291
J Clin Invest. 1981 Apr;67(4):1215-27
6259214
Am J Physiol. 1992 Dec;263(6 Pt 2):H1739-46
1481899
Kidney Int. 1987 Dec;32(6):900-7
2963169
Proc Natl Acad Sci U S A. 1980 Jan;77(1):675-8
6102381
Front Biosci. 2003 May 01;8:s377-90
12700051
Scand J Clin Lab Invest. 2001;61(5):395-400
11569487
Mol Cell Biochem. 1987 Sep;77(1):29-35
3122019
Miner Electrolyte Metab. 1995;21(1-3):72-6
7565467
Rev Endocr Metab Disord. 2006 Jun;7(1-2):113-21
17043762
Eur Heart J. 2003 Nov;24(22):2054-60
14613742
J Cardiovasc Pharmacol. 2001 Oct;38(4):491-9
11588519
Endocr Rev. 1991 Aug;12(3):291-301
1935823
Nephrol Dial Transplant. 1997 May;12(5):933-8
9175045
Am Heart J. 1985 Mar;109(3 Pt 1):539-45
4038842
Cardiovasc Res. 2008 Mar 1;77(4):722-31
18055578
Circulation. 1996 Nov 1;94(9):2241-7
8901678
Cardiovasc Res. 1998 Jan;37(1):34-41
9539855
Curr Opin Pharmacol. 2005 Dec;5(6):612-7
16181808